Pharmaceutical company Ellara is completing preparations for the opening of a small-scale peptide synthesis facility in the Vladimir Region. The launch of the site, which will allow for the localization of technological competencies currently absent in Russia, is scheduled for the first quarter of 2026.
Details of the project implementation were revealed during a working visit by Alexander Avdeev, Governor of the Vladimir Region, to the company’s manufacturing site in the Pokrov urban district. The visit focused on inspecting capacities and monitoring the execution of investment agreements, according to the official channel of the regional head.
Today, Ellara acts as one of the key drivers of the territory’s development. The plant manufactures over 70 injectable products, 80% of which are included in the Vital and Essential Drugs List (VED).
Restoring Competencies
The company’s new project is aimed at the import substitution of technologies. Construction of the facility is being carried out under an agreement signed at the Vladimir Investment Congress (VIC-2024).
“Currently, such competencies do not exist in Russia. Ellara plans to revive them. Production will be localized in our region.”
— Alexander Avdeev, Governor of the Vladimir Region
The company’s development strategy provides for further scaling. Under the next stage (VIC-2025 agreement), the construction of a new production building with an area of about 15,000 sq. m is planned by 2029.
